Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Single-arm Phase II Interventional Study to Evaluate the Activity and Safety of the Combination of Platinum-pemetrexed Based Chemotherapy Plus Lorlatinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) With Exclusively Extracranial Disease Progression on Lorlatinib.

NCT06378892 is registered in ClinicalTrials.gov with Centro di Riferimento Oncologico - Aviano as lead sponsor.

NCT NCT06378892
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06378892 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Single-arm Phase II Interventional Study to Evaluate the Activity and Safety of the Combination of Platinum-pemetrexed Based Chemotherapy Plus Lorlatinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) With Exclusively Extracranial Disease Progression on Lorlatinib.
Lead sponsor
Centro di Riferimento Oncologico - Aviano
Phase
Phase 2
Overall status
Recruiting
Start date
March 15, 2024
Completion date
May 31, 2028
Enrollment
45 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

alk gene mutation, non small cell lung cancer metastatic